Placebo-Controlled, Double-Blind Trial of Intravenous Ribavirin for the Treatment of Hantavirus Cardiopulmonary Syndrome in North America
Open Access
- 1 November 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (9) , 1307-1313
- https://doi.org/10.1086/425007
Abstract
Background. Ribavirin is active in vitro against hantaviruses, but the findings of an open trial of the use of intravenous ribavirin for the treatmenKeywords
This publication has 6 references indexed in Scilit:
- Active and Passive Vaccination against Hantavirus Pulmonary Syndrome with Andes Virus M Genome Segment-Based DNA VaccineJournal of Virology, 2003
- Humoral Immune Responses in the Hantavirus Cardiopulmonary SyndromeThe Journal of Infectious Diseases, 2000
- Outbreak of Hantavirus Infection in the Four Corners Region of the United States in the Wake of the 1997–1998 El Niño–Southern OscillationThe Journal of Infectious Diseases, 2000
- Intravenous Ribavirin for Hantavirus Pulmonary Syndrome: Safety and Tolerance during 1 Year of Open-Label ExperienceAntiviral Therapy, 1999
- Cardiopulmonary manifestations of hantavirus pulmonary syndromeCritical Care Medicine, 1996
- Prospective, Double-Blind, Concurrent, Placebo-Controlled Clinical Trial of Intravenous Ribavirin Therapy of Hemorrhagic Fever with Renal SyndromeThe Journal of Infectious Diseases, 1991